Synonyms
Atypical chronic myeloid leukemia, Philadelphia chromosome-negative (Ph1-); Chronic myelodysplastic/myeloproliferative disease; Juvenile chronic myelomonocytic leukemia; Mixed myeloproliferative/myelodysplastic syndrome; Overlap syndrome; Refractory anemia with ring sideroblasts associated with marked thrombocytosis (RARS-T)
Definition
The myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid neoplasms characterized at the time of their initial presentation by the simultaneous presence of myelodysplastic and myeloproliferative features, which prevent them from being classified as either myelodysplastic syndrome (MDS) or myeloproliferative neoplasm (MPN). The most common entities within the MDS/MPN group include chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia, BCR-ABL1negative (aCML), and juvenile myelomonocytic leukemia (JMML). A less well-defined group of MDS/MPN-like diseases include MDS/MPN unclassifiable (MDS/MPN-U) and a...
This is a preview of subscription content, log in via an institution.
References and Further Reading
Bacher, U., Haferlach, T., Schnittger, S., et al. (2011). Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia. British Journal of Haematology, 153, 149–167.
Itzykson, R., Kosmider, O., Renneville, A., et al. (2013). Prognostic score including gene mutations in chronic myelomonocytic leukemia. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 31, 2428–2436.
Kohlmann, A., Grossmann, V., Klein, H. U., et al. (2010). Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 28, 3858–3865.
Kosmider, O., Gelsi-Boyer, V., Ciudad, M., et al. (2009). TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica, 94, 1676–1681.
Orazi, A., Bennett, J. M., Germing, U., Brunning, R. D., Bain, B. J., Cazzola, M., Foucar, K., Thiele, J., Baumann, I., Niemeyer, C. M., Hasserhian, R. P., & Malcovati, L. (2017). Myelodysplastic/myeloproliferative neoplasms. Lyon: IARC.
Ricci, C., Fermo, E., Corti, S., et al. (2010). RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant. Clinical Cancer Research, 16, 2246–2256.
Wang, S. A., Hasserjian, R. P., Fox, P. S., et al. (2014). Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood, 123, 2645–2651.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this entry
Cite this entry
Geyer, J.T., Orazi, A. (2018). Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN). In: van Krieken, J. (eds) Encyclopedia of Pathology. Encyclopedia of Pathology. Springer, Cham. https://doi.org/10.1007/978-3-319-28845-1_4774-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-28845-1_4774-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-28845-1
Online ISBN: 978-3-319-28845-1
eBook Packages: Springer Reference MedicineReference Module Medicine